OSU's kidney dialysis technology provider has added about $36m to close its initial public offering, its shares having more than doubled in price.

The kidney dialysis technology provider has added about $36m to close its initial public offering, it shares having more than doubled in price.

Tencent is the largest shareholder of short-form video app developer Kuaishou, which is reportedly looking to boost its valuation to $50bn in a January offering.

Dell's stake in the software release technology provider is sized at almost $490m following an initial public offering in which it floated well above its range.

Lilly Asia Ventures achieved an exit as the gastrointestinal and liver disease drug developer priced its initial public offering in the middle of its range.

Salesforce Ventures will invest another $250m as the data management software provider floated above its range at a valuation just short of $29bn.

Baxter International scored an exit as dialysis machine developer Outset Medical floated above its range in an upsized offering.

Astellas and Celgene-backed immuno-oncology therapy developer Oncorus has filed to raise up to $86.3m following more than $150m in funding.

Small molecule drug developer C4 has fied for a $100m initial public offering, three months after the Dana-Farber Cancer Institute spinout raised a $170m round.

Kraft Group, Roche and Novartis are in line for exits after small molecule drug developer C4 filed for a $100m offering,